This clinical trial studies patients with Acute Myeloid Leukemia (AML) and Chronic Lymphocytic Leukemia (CLL). The study evaluates different treatment approaches based on the presence of minimal residual disease (MRD), which refers to cancer cells that may remain after initial treatment. For AML patients, the study compares standard intensity treatment involving stem cell transplantation with reduced intensity treatment. For CLL patients, the study examines whether treatment can be stopped early in patients who show no detectable disease.
The treatments used in this study include several anti-cancer medications: cytarabine, daunorubicin, etoposide, cladribine, mitoxantrone, obinutuzumab, ibrutinib, venetoclax, and fludarabine. Some patients may also receive cyclophosphamide, busulfan, or treosulfan as part of their treatment. The medications are given either through intravenous infusion or as oral tablets, depending on the specific drug.
The main purpose of this study is to determine if less intensive treatment can be as effective as standard treatment in patients who show no signs of remaining disease after initial therapy. The study will monitor patients’ survival, side effects, and whether the disease returns after treatment. Participants will be followed for several years to evaluate the long-term effectiveness of these treatment approaches.
France 
Germany 
Poland 
